on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. recently released its disclosure in accordance with the Irish Takeover Panel's rules concerning its stake in Avadel Pharmaceuticals plc. As of January 7, 2026, Vanguard owns and controls 5,865,407 US$0.01 ordinary shares of Avadel, representing a 6.02% interest. This information aligns with the parameters set by the Irish Takeover Panel Act, 1997.
In recent transactions, Vanguard purchased 2,030 shares and sold 66 shares at a price of 21.50 USD each. No new cash-settled or stock-settled derivative positions, nor any other relevant securities transactions, were reported.
The company confirmed absence of any indemnity or option arrangements, agreements, or understandings related to the securities or derivatives of Avadel Pharmaceuticals.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news